AbbVie (ABBV) Price on Solana

Israel "Izzy" Englander's Millennium Management added 840,718 shares of AbbVie in a recent filing, more than doubling the fund's position to approximately 1.5 million shares worth around $380 million. The move signals a significant institutional vote of confidence in the pharmaceutical giant, whose dividend has grown at a 5.9% average annual rate over the past five years — reaching $6.83 annually in 2026 from $2.28 a decade ago.

AbbVie's growth story is increasingly anchored by successors to its legacy Humira franchise: Skyrizi posted $9.99 billion in first-half 2026 sales, while Rinvoq contributed $4.64 billion. The company has also expanded through acquisitions, including an $11 billion deal for Apogee Therapeutics. AbbVie's price-to-sales ratio has risen to 7.2 from 6.3 earlier in the year, reflecting the market's growing recognition of its diversified pipeline across immunology, oncology, and aesthetics.

AbbVie has filed an application with the European Medicines Agency seeking approval for a subcutaneous induction regimen of Skyrizi in adults with moderately to severely active Crohn's disease, backed by Phase 3 AFFIRM trial data. The filing extends Skyrizi's reach beyond its existing immunology indications and adds a meaningful near-term regulatory catalyst to the drug that, alongside Rinvoq, now accounts for close to half of AbbVie's total revenue.

Analysts peg AbbVie's fair value at roughly $273, implying about 6.6% upside from the stock's late-August trading price near $255. The elevated P/E of approximately 72x — compared to a peer average around 29x — reflects a pipeline that spans the Capstan CAR-T program, an obesity-focused amylin analog in-licensed from Gubra, and next-generation siRNA platforms, in addition to the Apogee Therapeutics acquisition. Faster-than-expected competitive pressure on key drugs or disappointing returns from R&D and acquisition spending remain the primary risks to that premium.

AbbVie presented lung cancer pipeline data at the World Conference on Lung Cancer in August 2026, spotlighting two investigational programs — ABBV-1480 and ABBV-706 — that span bispecific antibodies and antibody-drug conjugates in both first-line and relapsed non-small cell lung cancer settings. The readouts, which included Temab-A trial data, showed high objective response rates with manageable safety profiles, reinforcing oncology as a genuine third pillar alongside the company's established immunology and neuroscience franchises rather than a speculative side bet.

Near-term revenue remains anchored to Skyrizi and Rinvoq holding the immunology line, but AbbVie's longer-range case — projected 8.2% annual revenue growth toward $81.5 billion by 2029 — depends on newer oncology and neuroscience assets collectively absorbing the pricing and patent pressure that has continued to erode legacy Humira economics. Sustained global pricing pressure is the primary risk the company's financial projections must navigate as the oncology pipeline matures toward potential commercialization.

AbbVie's post-Humira transition is showing clear momentum in Q2 2026: Skyrizi delivered $5.51 billion in revenue (up 24.4% year-over-year) and Rinvoq added $2.53 billion (up 24.5%), pushing combined immunology sales from Humira's former blockbuster replacement pair to roughly $8 billion — compared to just $756 million left in Humira's declining royalty stream. Total company revenue grew 10.2% to $16.99 billion, with the immunology segment up 15.1% to $8.79 billion even as Humira itself fell 35.9%. Neuroscience also contributed meaningfully, growing 20.3% to $3.23 billion on strength from Vraylar, Botox Therapeutic, and Qulipta.

The headline risk is concentration: Skyrizi and Rinvoq together now account for approximately 47% of total quarterly revenue, a degree of dependence that analysts flag as a structural vulnerability if either franchise faces a competitive or safety setback. Oncology revenue declined 1.5% and aesthetics was essentially flat, offering little diversification buffer. AbbVie also trimmed its full-year adjusted EPS guidance slightly — to a range of $13.87–$14.07 from $13.91–$14.11 — citing dilution from the proposed Apogee Therapeutics acquisition, a signal that near-term inorganic moves may weigh on earnings even as organic immunology growth continues.

AbbVie reported that SKYRIZI is holding its ground in immunology despite a new oral psoriasis competitor that entered the market in March 2026, with quarterly sales up 24% and management stating that new-prescription growth actually accelerated during the competitive pressure. The company trimmed its full-year 2026 adjusted EPS guidance slightly to $13.87–$14.07, attributing the reduction to dilution from the Apogee Therapeutics acquisition rather than any deterioration in core business performance, and the stock has remained near 52-week highs.

The unresolved question analysts are watching is whether AbbVie can replicate that commercial precision in its next wave of clinical programs. Pivotal data for both RINVOQ in hidradenitis suppurativa and a second HS candidate, lutikizumab, are expected later in 2026 — but both trials carry a specific structural risk: the widespread use of GLP-1 weight-loss drugs could artificially boost placebo response rates by improving HS symptoms independent of the study drug, making it harder for AbbVie's candidates to clear statistical hurdles even if they work.

AbbVie's Q2 2026 results beat consensus — revenue of $16.99B topped the $16.79B estimate and adjusted EPS of $3.65 edged past $3.61 — but a lowered full-year EPS guidance midpoint of $13.97 (down roughly 1.5%) pushed shares from around $257 to $244 post-earnings. The five most revealing analyst questions on the call dug into what drives growth beyond those headline numbers.

Morgan Stanley pressed on SKYRIZI's subcutaneous induction approval timeline and manufacturing capacity; management said the review is proceeding on schedule with no supply concerns. JPMorgan asked whether competition was eating into SKYRIZI's psoriasis franchise, and the company countered that new patient starts actually rose after rival launches. UBS focused on Tevapadon, AbbVie's Parkinson's therapy entering commercialization, with management flagging a modest initial ramp tied to formulary timing while pointing to its brain shuttle technology as a patient-convenience differentiator. Wells Fargo sought clarity on lutikizumab's hidradenitis suppurativa efficacy and how GLP-1 use among patients would be handled in trials; management cited strong phase 2 data and said a dual strategy pairing lutikizumab with RINVOQ remains on track.

AbbVie shares fell nearly 3% after the company reported Q2 2026 results that disappointed on the bottom line and trimmed full-year guidance. Adjusted net income of $3.65 per share fell short of the analyst consensus of $3.71, despite revenue of just under $17 billion — a 10%-plus year-over-year gain that actually beat the $16.77 billion estimate. The sell-off was driven primarily by the earnings miss and a guidance reduction: AbbVie now expects full-year 2026 adjusted earnings of $13.87 to $14.07 per share, below the $14.12 consensus, with the company citing its $10.9 billion acquisition of Apogee Therapeutics as the reason for the recalibration.

Segment results were mixed. Immunology — AbbVie's largest division — grew 15% to $8.79 billion, led by Skyrizi, while neuroscience expanded 20% to $3.2 billion. Oncology was the weak spot, declining nearly 2% to $1.65 billion. Some analysts remain constructive on the longer-term outlook, pointing to the strength of AbbVie's drug portfolio and arguing the guidance cut reflects deliberate strategic investment rather than a fundamental deterioration in the business.

The European Commission has approved AbbVie's RINVOQ® (upadacitinib) 15 mg once daily for non-segmental vitiligo (NSV) in adults and adolescents aged 12 and older who are candidates for systemic therapy — making RINVOQ the first and only systemic treatment authorized in the EU for this indication. NSV accounts for roughly 84% of all vitiligo cases, a chronic autoimmune disease in which the immune system destroys melanocytes, producing irregular white patches that carry substantial psychological burden for patients who previously had no approved systemic options.

The approval is supported by Phase 3 Viti-Up data from two replicate, placebo-controlled studies enrolling 614 participants at 90 sites worldwide, which demonstrated statistically significant improvements in total body repigmentation (T-VASI 50) and facial repigmentation (F-VASI 75) at week 48, alongside disease stabilization in actively advancing cases with a safety profile consistent with RINVOQ's established indications. The clearance extends RINVOQ's EU label to nine indications spanning rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, and alopecia areata among others, further broadening AbbVie's dermatology franchise as the company continues diversifying revenue following the loss of Humira exclusivity.

AbbVie's Phase 3 EPCORE DLBCL-1 trial for epcoritamab — developed with Genmab for diffuse large B-cell lymphoma — failed to meet its overall survival primary endpoint in the U.S. portion, casting doubt on the drug's long-term commercial potential. The setback is a meaningful pipeline blow, though epcoritamab already has regulatory approvals in other lymphoma indications that remain unaffected by this trial result.

Despite the news, a fair-value model pegs ABBV at roughly $266.89 versus its recent close of $259.36 — implying about 2.8–3% undervaluation even after the stock's 30% gain over the prior 90 days. AbbVie trades at a steep 127.5x P/E relative to the industry's 16.9x average, a premium analysts attribute to its diversified pipeline and active business development, highlighted by the recent $10.9 billion Apogee acquisition. The modest implied upside suggests the market views the epcoritamab setback as contained rather than existential for the broader franchise.

AbbVie announced on June 22, 2026 that it will acquire Apogee Therapeutics for $10.9 billion in cash, funded through new debt to preserve existing liquidity. The deal's key asset is zumilokibart, an investigational antibody for eczema that is expected to deepen AbbVie's immunology portfolio alongside its established growth drivers Skyrizi and Rinvoq.

Despite the large price tag, analysts argue the acquisition poses little threat to AbbVie's dividend. The company ended 2025 with $17.8 billion in free cash flow and holds Dividend King status — more than 50 consecutive years of dividend increases — a streak management has strong incentive to protect. The precedent from AbbVie's $63 billion Allergan acquisition in 2020 is instructive: rather than pressuring the dividend, payouts grew 46.6% in the years that followed.